Tempus AI shares slide 7% as Q4 results disappoint

Published 24/02/2025, 22:18
Tempus AI shares slide 7% as Q4 results disappoint

CHICAGO - Tempus AI , Inc. (NASDAQ:TEM) reported fourth quarter results Monday, following which shares were down 7% in after-hours trading.

The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.

Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.

"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year," said Eric Lefkofsky, Founder and CEO of Tempus.

For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.

Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.